TCM
CRSP icon

Triumph Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Triumph Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.45K Hold
100
– – ﹤0.01% 1324
2026
Q1 		$4.76K Hold
100
– – ﹤0.01% 1324
2025
Q4 		$5.24K Buy
+100
New +$5.99K ﹤0.01% 1248

Other funds holding CRSP

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SC
Slow Capital Greenbrae, California $857M AUM 38.3% 1-Year Est. Return
CIC
Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $900M AUM
BIP
Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
LIM
Leavell Investment Management Mobile, Alabama $2.74B AUM 26.51% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return

Triumph Capital Management's CRSP Position: Q2 2026 in Review

Triumph Capital Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 100 shares worth $5.45K. The position accounts for ﹤0.01% of the portfolio, ranked #1324.

Triumph Capital Management first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. 78 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Triumph Capital Management held 100 shares of CRISPR Therapeutics worth $5.45K as of Q2 2026.
  • Triumph Capital Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1324 holding.
  • Triumph Capital Management first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 78 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.